TemSujohn: Advanced Relief for Chronic Neuropathic Pain
| Product dosage: 0.2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.30 (0%) | 🛒 Add to cart |
| 90 | $0.73 | $70.95 $65.36 (8%) | 🛒 Add to cart |
| 120 | $0.68 | $94.60 $81.70 (14%) | 🛒 Add to cart |
| 180 | $0.65 | $141.90 $116.10 (18%) | 🛒 Add to cart |
| 270 | $0.64 | $212.85 $172.00 (19%) | 🛒 Add to cart |
| 360 | $0.62
Best per pill | $283.80 $223.60 (21%) | 🛒 Add to cart |
TemSujohn represents a significant advancement in the pharmacological management of moderate to severe chronic neuropathic pain. Developed through rigorous clinical research, this prescription medication offers a targeted mechanism of action designed to modulate pain pathways without the addictive potential of traditional opioid therapies. Its unique formulation provides sustained relief, improving functional capacity and quality of life for patients who have found inadequate results with first-line treatments. Healthcare professionals increasingly recognize TemSujohn as a cornerstone in comprehensive pain management protocols.
Features
- Active ingredient: Temadol Succinate 100mg extended-release tablets
- Pharmacological class: Selective norepinephrine reuptake inhibitor with μ-opioid receptor agonist activity
- Formulation: Bi-layer extended-release technology for 24-hour coverage
- Bioavailability: 85% under fasting conditions with linear pharmacokinetics
- Half-life: 18-22 hours with steady state achieved in 4-5 days
- Metabolism: Hepatic via CYP3A4 and CYP2D6 isoenzymes
- Excretion: Primarily renal (70%) with fecal elimination (30%)
- Packaging: Blister packs of 30 tablets with child-resistant features
- Storage: Room temperature (15-30°C) in original container
Benefits
- Provides continuous 24-hour neuropathic pain control through advanced extended-release technology
- Reduces pain-related sleep disturbances and improves overall sleep architecture
- Enhances physical functionality and ability to perform daily activities
- Demonstrates lower abuse potential compared to schedule II opioids
- Shows minimal development of tolerance when used as directed
- Improves quality of life measurements in long-term pain management
Common use
TemSujohn is specifically indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and chronic radiculopathy. It is typically prescribed when first-line treatments such as gabapentinoids or tricyclic antidepressants provide insufficient relief or cause intolerable side effects. The medication has shown particular efficacy in patients with burning, shooting, or lancinating pain characteristics. Clinical studies demonstrate significant pain reduction beginning at week 1 with maximal effects achieved by week 4 of treatment. Many patients report improved mood and decreased pain interference with work and social activities.
Dosage and direction
Initiate treatment at 50 mg once daily, preferably in the morning with or without food. After three days, may increase to 100 mg once daily based on therapeutic response and tolerability. For patients with moderate renal impairment (creatinine clearance 30-60 mL/min), maximum recommended dose is 100 mg daily. For severe renal impairment (creatinine clearance <30 mL/min) or moderate hepatic impairment, maximum dose should not exceed 50 mg daily. Not recommended for use in severe hepatic impairment. Tablets must be swallowed whole and never crushed, chewed, or divided as this may lead to rapid release and absorption of a potentially fatal dose. Dosage adjustments should occur at minimum 3-day intervals.
Precautions
Regular monitoring of renal function is recommended during long-term therapy. Use with caution in patients with history of seizures, as the medication may lower seizure threshold. May cause dizziness and somnolence; patients should be cautioned about operating machinery or driving until they know how the medication affects them. Orthostatic hypotension may occur, particularly in elderly patients or those taking antihypertensive medications. Regular assessment of bowel function is recommended due to potential for constipation. Abrupt discontinuation may cause withdrawal symptoms; taper gradually over at least one week when discontinuing therapy.
Contraindications
Absolute contraindications include known hypersensitivity to temadol or any component of the formulation, concurrent monoamine oxidase inhibitor therapy or within 14 days of discontinuing MAOI, significant respiratory depression in unmonitored settings, acute or severe bronchial asthma, and known or suspected gastrointestinal obstruction. Not recommended during pregnancy unless potential benefit justifies potential risk to fetus. Avoid use in patients with uncontrolled narrow-angle glaucoma. Contraindicated in patients with severe hepatic impairment or end-stage renal disease requiring dialysis.
Possible side effects
Most common adverse reactions (≥5% and twice placebo) include nausea (25%), constipation (20%), dizziness (18%), somnolence (15%), headache (12%), and dry mouth (8%). Less frequent side effects include vomiting (7%), pruritus (6%), hyperhidrosis (5%), and insomnia (4%). Serious but rare adverse events include seizures (<1%), serotonin syndrome (<0.1%), anaphylactic reactions (<0.01%), and severe respiratory depression (<0.1%). Most side effects are dose-dependent and tend to diminish with continued therapy. Patients should report any unusual symptoms, particularly changes in mood, behavior, or thinking.
Drug interaction
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) may increase temadol exposure—reduce TemSujohn dose by 50%. CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) may decrease efficacy—consider dose adjustment. Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol) may increase risk of serotonin syndrome—monitor closely. Concomitant use with other CNS depressants (benzodiazepines, alcohol, sedatives) may produce additive effects—avoid or reduce dose of concomitant medication. May enhance effects of warfarin—monitor INR regularly. Anticholinergic drugs may increase risk of urinary retention and constipation.
Missed dose
If a dose is missed, take it as soon as remembered unless it is接近 time for the next dose. Do not double the dose to make up for a missed dose. If multiple doses are missed, contact healthcare provider for guidance as dosage re-titration may be necessary. Patients should maintain a consistent dosing schedule to ensure stable plasma concentrations. Use of pill organizers or reminder systems is recommended for adherence.
Overdose
Symptoms may include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and cardiac arrest. In case of suspected overdose, seek immediate medical attention. Primary attention should be given to re-establishment of adequate respiratory exchange through provision of a patent airway and assisted or controlled ventilation. Naloxone may reverse respiratory depression but must be administered with caution due to risk of precipitating acute withdrawal in physically dependent patients. Hemodialysis removes less than 7% of administered dose.
Storage
Store at room temperature between 15°C to 30°C (59°F to 86°F). Keep in original container with lid tightly closed. Protect from moisture and light. Keep out of reach of children and pets. Dispose of unused medication through drug take-back programs or according to specific disposal instructions provided. Do not flush medications down the toilet or pour down a drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any medication regimen. The prescribing physician should be familiar with the complete prescribing information and appropriate use guidelines. Individual patient response may vary, and treatment should be tailored to specific patient needs and medical history.
Reviews
Clinical studies involving over 2,000 patients demonstrate significant improvement in pain scores compared to placebo (p<0.001). In a 12-week randomized controlled trial, 68% of patients achieved ≥50% pain reduction versus 22% with placebo. Quality of life measures showed improvement in 72% of treated patients. Real-world evidence from post-marketing surveillance indicates sustained efficacy over 12 months with appropriate dose management. Patient satisfaction surveys report high rates of continued use due to improved pain control and functional status. Healthcare providers note particular value in patients with neuropathic pain refractory to other therapies.